CG Oncology, Inc. (CGON) closed the last trading session at $26.42, gaining 2.2% over the past four weeks, but there could be ...

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...

CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

We recently published a list of the 12 Best IPO Stocks to Buy in 2025. In this article, we are going to take a look at where ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

March 28, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...

Across the recent three months, 4 analysts have shared their insights on CG Oncology CGON -2.73% Get Free Report , expressing a variety of opinions spanning from bullish to bearish. Summarizing their ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive ...

CG Oncology, Inc. (CGON) closed the last trading session at $26.42, gaining 2.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...